Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.35, read 2026-11-03
Ethical does not pass the values gate
Price38.56 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-05Read Distribution41.54-7.2% to today ✓Markdown gives way to Distribution after a 20% slide in 11 days
2026-10-25Read Markdown52.24-26.2% to today ✓Distribution gives way to Markdown after a 17% slide in 2 weeks
2026-10-11Read Distribution63.24-39.0% to today ✓Markup gives way to Distribution after an 11% slide in 9 days
2026-10-02Read Markup71.09-45.8% to today Accumulation gives way to Markup after a 19% rise in 11 days
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Ambiq Micro, Inc. holds its Distribution at $38.56. Consolidating, no directional conviction, held for 67 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 67 days
Price at the screen
$38.56
Valuation
N/A trailing · -191.66 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.37%
Below 33%
Interest-bearing debt is just 0.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
79.90%
Below 49%
Money owed to the company is 79.9% of assets, above the 49% limit.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Ambiq Micro,'s business is fine, but its receivables are about 80% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AMBQ's ethical verdict changes
Today AMBQ does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Fair value under review. Our model's value is 2.20x the price, above our 1.35x limit. We show no fair value, margin of safety or value read built on it until the review clears.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Ultra Low Power Chips Still Burning Cash
Picture a fitness band that lasts weeks on a single charge instead of hours. Ambiq supplies the chips that make such claims possible through its sub-threshold design. Yet the business remains deep in losses and the shares sit slightly above our fair value with no margin of safety on offer.
Revenue growth of 59 percent looks impressive but forward earnings are negative and profit margins sit at minus 47 percent. Return on equity is minus 24 percent. In a cyclical semiconductor industry that pattern usually reflects temporary demand spikes rather than durable advantage.
High growth can disappear quickly once handset and IoT cycles turn. The ethical screen passes yet the combination of losses and stretched valuation leaves nothing worth pursuing here. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AMBQ trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-07Distribution$38.56+9.5%Entry 17
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 9.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-06Distribution$35.22-15.2%Entry 16
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 15.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04Markdown$44.68-6.5%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markdown$47.77+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markdown$47.77-8.6%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter.
2026-10-25Markdown · changed$52.24+0.3%Entry 11
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 18% above its long-term trend line with momentum reading oversold. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter.
2026-10-18Distribution$52.08-17.6%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 17.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 11.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
2026-10-02Markup · changed$71.09+18.7%Entry 8
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading overbought. Our forward projection puts the odds of a 10% gain over the next month near 46%. The street (5 analysts) rates it none, with a mean price target of $70. Since the last review it its composite score eased.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.